- Recent Funding
- Investors
- Shangbay Capital
Shangbay Capital portfolio
Shangbay Capital has 1 portfolio company on record at Recent Funding.
About this page
Its most recent investment on record is Contraline's $10.7M Series A round in October 2021, alongside The Syndicate.com, Smith Ventures, Rhia Ventures and 6 others. That company is in Health and bio.
What Shangbay Capital invests in
- Health and bio · 1 · 100%
How Shangbay Capital invests
| Stage | Deals | Capital in rounds |
|---|---|---|
| Series A | 1 100% | $10.7M |
Shangbay Capital portfolio companies
CContraline$10.7MSeries A · Oct 2021
| Company | Round with Shangbay Capital | Total raised | Latest raise |
|---|---|---|---|
Health and bio |
Series A · $10.7M | $105.45M | Jun 2, 2026 Series B+ |
Most frequent co-investors
FFounders Fund1 shared round · last Oct 26, 2021
MMetaplanet Holdings1 shared round · last Oct 26, 2021
TThe Syndicate.com1 shared round · last Oct 26, 2021
- SSmith Ventures1 shared round · last Oct 26, 2021
RRhia Ventures1 shared round · last Oct 26, 2021
MMBX Capital1 shared round · last Oct 26, 2021LLAUNCH1 shared round · last Oct 26, 2021
- JJaffray Woodriff1 shared round · last Oct 26, 2021
GGraphene Ventures1 shared round · last Oct 26, 2021
Similar investors
AAccelia Capital1 company · 1 deal in 12 mo
BBioGenerator Ventures1 company · 1 deal in 12 mo
BBiospring Partners1 company · 1 deal in 12 mo
CColossa Ventures1 company · 1 deal in 12 moFFirst Imagine!1 company · 1 deal in 12 mo
MMaxis1 company · 1 deal in 12 mo
Investors whose portfolios on Recent Funding center on the same category (Health and bio).
How this is counted
Share is of the 1 round on Recent Funding that name Shangbay Capital. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.
Portfolio companies are the companies on Recent Funding with a round that lists Shangbay Capital, which is a subset of its real portfolio. API: /api/v1/investors/shangbay-capital (get a free API key). More: the most active VC firms and new venture capital funds.